Tim M (@TJMeehan1) profile picture
Joined April 2015
Photo by Tim M (@TJMeehan1)Photo by Tim M (@TJMeehan1)Photo by Tim M (@TJMeehan1)Photo by Tim M (@TJMeehan1)Photo by Tim M (@TJMeehan1)Photo by Tim M (@TJMeehan1)Photo by Tim M (@TJMeehan1)Photo by Tim M (@TJMeehan1)Photo by Tim M (@TJMeehan1)Photo by Tim M (@TJMeehan1)
1/ There was a different COVID vaccine all along. Here's the paper trail on how it got held back. Novavax's Nuvaxovid is a traditional protein vaccine, the same platform family as the hepatitis B shot. In a roughly 30,000-person trial against a saline placebo: 90.4% efficacy. No mRNA. No lipid nanoparticles. In a UK randomized trial, its side effects ran milder than the mRNA shots. nih.gov/news-events/news-rel…
1
1
7
228
$NVAX convertible notes: what happens if the stock runs to $13? Novavax has $225M of 4.625% convertible notes due Sept 1, 2031, converting at $11.14/share (about 20.2M shares). Another ~$26.5M of 5% notes due 2027 are still out, and there's a new $50M loan due 2031 that is not convertible. Note terms (8-K, Aug 27, 2025): • Before June 1, 2031, holders can convert only if certain trigger events happen. The standard trigger is the stock trading above 130% of the conversion price (about $14.48) for 20 of 30 trading days. $13 wouldn't qualify. • From June 1, 2031 to maturity, holders can convert anytime. • Novavax can call the notes and force conversion only after Sept 5, 2028, and only if the stock stays above ~$14.48. • On conversion, Novavax picks cash, shares, or a mix, so conversion doesn't automatically mean new shares. • In a takeover, the conversion price can drop to $8.74 (up to ~25.7M shares). Market practice: Holders rarely convert early. The notes pay 4.625% interest and still carry option value, and both disappear the moment they convert. So funds usually hold the notes, adjust their short hedge as the stock moves, or sell the notes. Most conversions happen right before maturity or when the company forces them with a call. Bottom line: at $13, holders would most likely keep collecting interest and hold. Hedge shorts tied to the notes would typically grow as the price rose, not shrink.
2
6
180
Re: Convertible Notes I asked Grok Bot to go hunting for who actually holds $NVAX's $225M 4.625% converts due 2031. Novavax never named them. The August 2025 deal was a private placement, no underwriter, with J. Wood Capital as sole placement agent and Leerink as an adviser. The buyers were existing 2027 noteholders plus new investors, listed on exhibits that were not filed publicly. What the filings do say matters. At closing, J. Wood bought about 1.2 million $NVAX shares, roughly $10 million, from the noteholders at a discount and locked them up for 30 days. J. Wood's own write-up says that purchase was structured to "mitigate hedging activity," so the buyers wouldn't have to short into the open market overnight. That's as close as you'll get to written confirmation that these holders hedge by selling or shorting $NVAX. The 2031 notes barely show up in 13Fs, typical of restricted private-placement paper. The only 13F name I found was Skaana Management, at $2 million principal in late 2025, gone by mid-2026. N-PORT mutual-fund filings show small slices at JNL Multi-Manager Alternative ($415k), PACE Alternative Strategies ($156k), Franklin Alternative Strategies ($126k), and Lazard Enhanced Opportunities ($54k plus a swap). Those same funds are short $NVAX stock against the notes, in about the ratio you'd expect for a convertible hedge, but that's well under 1% of the issue. The other ~$224 million is still unidentified. So some of the 46.3 million shares short (165 million outstanding as of October 30) is almost certainly hedge inventory. At around $7.50, my rough guess is that a full delta hedge would only be a few million shares, a slice of the short, not the whole thing. If the stock runs, Novavax can settle conversions in cash, shares, or a mix, and can't call the notes until after September 5, 2028, and only if the stock holds above about $14.48.
3
74
"I don't wanna get any of my facts wrong." That's former @US_FDA Commissioner and current @pfizer board member @ScottGottliebMD on @DrMarcSiegel's @SIRIUSXM Doctor Radio show, seconds before he got the facts WRONG. Twice. To millions. 1. Gottlieb: "I think it's an ALUMINUM based [adjuvant]… a derivative of ALUM." FALSE. FDA's own label: Matrix-M is saponin extracts from the soapbark tree, Quillaja saponaria, plus cholesterol and phosphatidylcholine. ZERO aluminum. @Novavax markets it as "non-aluminum." That's the most basic fact about the product. 2. Gottlieb: "Developed at NIH… around the time that I was at FDA. So I remember it." You remember WRONG. Matrix-M came from Isconova, a Swedish spinoff Novavax bought in 2013 (SEC filings). Not NIH. Not your FDA years. 3. Siegel: "comes from tree bark… in the Shingrix vaccine… I don't know where the NOVAVAX one does come from." Marc, it's the SAME TREE. Shingrix's QS-21 is a Quillaja saponaria saponin. So is Matrix-M. You were ONE sentence from the truth and the Pfizer board member steered you back to "alum." Nobody corrected it. 4. Siegel: "It's actually GENERATED IN INSECTS." It's made in Sf9 insect cells in sterile bioreactors, the same kind of platform behind Flublok. The protein shot ALWAYS gets the creepy framing. mRNA never does. 5. The side-effect smear. COMPARE trial (@OHSUNews, randomized, double-blind, 1,000 adults, 2026) vs @moderna_tx mNEXSPIKE: • Moderate-to-severe systemic: 43.1% Nuvaxovid vs 61.3% mRNA • Moderate-to-severe local: 38.7% vs 58.7% The protein shot was the GENTLER one. Not close. 6. Gottlieb: "Haven't gotten as much commercial traction." Are you KIDDING me? FDA sat on the EUA until July 2022, after a 21-0 VRBPAC vote, 19 months after mRNA. Then the 2025 BLA blew past its goal date and came back narrowed with a new postmarketing trial under Prasad, since driven out of CBER. Kneecap a product, then sneer at its sales. Now the part that should make everyone furious. Gottlieb RAN FDA (2017-2019) and walked onto Pfizer's board 83 DAYS after leaving. He chairs its Regulatory & Compliance Committee and sits on Science & Technology. 2025 director pay: $393,500, plus 48,544 Pfizer stock units (2026 proxy). Pfizer sells Comirnaty, Nuvaxovid's direct competitor. The kicker: in Jan 2026 Pfizer LICENSED Matrix-M from Novavax. $30M upfront, up to $500M in milestones. The company paying him is paying for this EXACT adjuvant, and he calls it aluminum on national radio. Novavax's macaque data has been public since Aug 2020: protection in nose AND lungs. Then ~90% efficacy in two Phase 3s in @NEJM. Taxpayers put $1.6B in through Warp Speed. So pick one, Scott. You don't know what's in a vaccine your own company just licensed the adjuvant from, or something else is going on. And where was your conflict disclosure while you trashed the competitor? @ScottGottliebMD @DrMarcSiegel: correct the record. On air. @MartyMakary @SecKennedy @HHSGov: this is the revolving door. Non-mRNA. Protein-based. Tree-bark adjuvant. ~90% efficacy. Fewer side effects than mRNA head-to-head. Ask for Nuvaxovid BY NAME. @sanofi $NVAX $PFE $SNY $MRNA
Drs'. Siegel and Gottlieb (Former FDA commissioner and Pfizer board member) on Sirius Dr. Radio today told their listeners that Novavax probably uses ALUMINUM as an adjuvant three separate times and that the Novavax covid vaccine is GENERATED IN INSECTS. Talk about disinformation! Incompetent or Corrupt ??? There are only two possiblities... "Dr. Siegel... Great answer. And of course, with COVID, you also have the NOVAVAX vaccine, which is the protein adjuvant vaccine, but that's not been getting the same uptick, uh, or uptake as, as the mRNA vaccines, but you could argue that that's a reasonable alternative. Dr. Gottlieb: It's an alternative. You know, they've had, uh, and I don't know where they're at this season, but historically there's been some manufacturing challenges in terms of just producing enough of it, and they haven't gotten as much commercial traction with it. Um, but a very efficacious vaccine uses, uh, again, uses an adjuvant, I think it's an ALUMINUM based, it's a new adjuvant that was developed at NIH that I think is an ALUMINUM based adjuvant or derived from that. Um, so a more traditional, to your point, more traditional vaccine, a protein-based vaccine that's adjuvanted. Dr. Siegel: • 12:26 Just to clear for the listener, um, that a couple of points that Scott made, I want to clarify. Adjuvant is a chemical or some type of derivative that boosts the ability for essentially a nanoparticle to get into your body and, and to the point where it provokes an immune response. The, the mRNA vaccine comes in on a lipid nano nanoparticle and actually is able to do that without that boosting adjuvant. And sometimes the adjuvant actually comes from tree bark. I know that it does in the, uh, Shingrix vaccine, which is a protein adjuvant vaccine. Again, protein with a boost, a protein with a boost. I don't know where the, uh, the NOVAVAX one does come from, but it's actually GENERATED IN INSECTS. Right. Dr. Gottlieb: • 13:13 The, so the, THE PROTEIN SUBUNIT IS, and I believe the, i, the adjuvant used in a novavax vaccine as a newer adjuvant that was developed at NIH was developed around the time that I was at FDA. So I remember it, I don't, I, i, I don't wanna get any of my facts wrong, but I believe it is a, it is a sort of derivative of ALUM, which is the traditional vaccine, but a newer formulation of it. Um, so it, it, it, you know, it's a, it uses a new approach to an old technology, and you're right, the, the adjuvant that's in the Shingrix vaccine, which is also used in some of their other vaccines, uh, is a very immunogenic adjuvant. And that's why some patients get an immune response to the Shingrix vaccine, particularly a second dose. Some of that is from the adjuvant itself, which is very, a very immunogenic, very effective adjuvant, but obviously the more effective the adjuvant, uh, to your point about this, it's stimulating an immune response. And so you're gonna get an immune reaction to the vaccine itself, and, you know, that's gonna be vaccine side effects, sore r maybe a, a low grade fever, the kinds of effects we feel sometimes after we get a, a vaccine." @Novavax @sanofi siriusxm.com/player/show/doc…
1
1
1
12
559
The best advertisement you'll see today
151
1,501
122
8,726
448,436
Here's a thought for $NVAX and $PFE holders that the market isn't pricing in. In January, $PFE paid @Novavax $30M upfront for a non-exclusive license to use Matrix-M in up to two infectious diseases. Pfizer has already picked the first one, and neither company will say which. Each disease can earn $NVAX up to $70M in development milestones and $180M in sales milestones, plus high mid-single-digit royalties on sales. In February, a Novavax patent application went public: "Pneumococcal Conjugate Vaccines with Saponin-Based Adjuvants." They added Matrix-M to off-the-shelf Prevnar 13. In mice, antibody titers were 7.6x higher after two doses and 8.3x higher after three, with better bacterial killing across serotypes. Novavax's own investor deck says that could mean a more potent vaccine that needs less antigen per dose. Now look at where @pfizer is going: - The Prevnar family did $6.49B in 2025. It's $PFE's biggest vaccine and its No. 2 product overall. - Pfizer skipped ahead to a 35-valent adult Prevnar. It's due to enter the clinic by the end of 2026 and promises "next-generation technology" to boost serotype 3, which has always been the weak spot. - @Merck's $MRK Capvaxive (21-valent) is already competing for adults, and @Vaxcyte's $PCVX 31-valent VAX-31 just hit its Phase 3 endpoints, with a filing targeted for early 2028. - Older Prevnar patents are starting to roll off. $PFE needs a new moat. The catch with 35 serotypes is that every one adds polysaccharide and carrier protein to the same shot. The more you pack in, the harder it is to get a strong response to each serotype. An adjuvant that does more with less antigen solves exactly that problem. What it could do for $PFE: - Dose sparing: less antigen per serotype, which lowers cost of goods and leaves room to add serotypes. - Stronger responses on the hard serotypes, like 3. - An edge $MRK and $PCVX can't match on serotype count alone. When everyone is racing on breadth, you win on response quality. - A new formulation with its own data and IP as the older patents expire. What it could do for $NVAX: do the napkin math. A royalty of about 6% on a $6.5B franchise is roughly $390M a year, before milestones and adjuvant supply. Even a slice of that is recurring revenue that doesn't depend on one COVID season. To be fair, nobody has confirmed pneumococcal is the field. Pfizer hasn't said, the 35-valent hasn't started trials, and it would take years. But $PFE paid cash for the license, Novavax's own patent shows Matrix-M working with Prevnar, and Pfizer's next Prevnar needs exactly what Matrix-M does. That's a lot of dots lining up. The same Matrix-M adjuvant is in a vaccine you can get right now: Nuvaxovid, the protein-based COVID shot from @Novavax and @sanofi. In April, the randomized, double-blind COMPARE trial of 1,000 US adults ran it head-to-head against @moderna_tx's newest mRNA shot, mNEXSPIKE: - Moderate-to-severe body-wide side effects: 43% with Nuvaxovid vs 61% with mNEXSPIKE - Moderate-to-severe arm reactions: 39% vs 59% - Side effects bad enough to stop normal daily activities: under 1 in 10 vs 1 in 5 - People who'd definitely pick the same shot next year: 30% vs 16% If Pfizer thinks Matrix-M is good enough for its crown jewel, it only makes sense that other pharmas will too. And don't forget the potential cancer applications. $NVAX $PFE $MRK $PCVX $SNY $MRNA
2
15
685
On the cancer point: this isn't just hope. Novavax's Q2 2026 deck has a slide called "Why Oncology, Why Now: Matrix-M Opportunity," and at @Jefferies on Nov 17, management said internal preclinical cancer work came back very positive. The focus is durable CD8 T-cell responses, which is what therapeutic cancer vaccines need. They have an MTA with a top-10 pharma in oncology, and the next tranche of data is expected by early 2027. $NVAX
2
104
Replying to @TJMeehan1 @DrTrozzi
Tim, I think you'll like this one. We should name it the TimM video...
1
1
39
12/ Meanwhile, Blackstone committed up to $750M to Moderna's mRNA flu program in 2024. FDA approved Moderna's mRNA flu shot on Aug 5, 2026. And on Sept 23, 2026, the Pentagon (now the Department of War) awarded Flagship a contract worth up to $47M over five years for countermeasure technology. blackstone.com/news/press/bl… fda.gov/media/194121/downloa… fiercebiotech.com/biotech/de…
1
26
13/ Two asks. @RobertKennedyJr: reinstate the placebo-controlled studies FDA dropped in August. Science needs a fair fight and a real answer. And if you're 65+, or 12-64 with a high-risk condition, ask your doctor or pharmacist for Nuvaxovid by name. FDA approved its 2026-27 formula on Aug 27. Protein, not instructions.
1
32